Affinivax, Inc. (“Affinivax”), a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS™ (Multiple Antigen Presenting System) platform, today announced that Steven Brugger, president and CEO of Affinivax, will present a company overview at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 9:30 a.m. ET.
About Affinivax, Inc.
Affinivax is a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines designed to induce a broad and robust protective immune response to both disease-relevant polysaccharides and disease-relevant proteins in a single vaccine. Affinivax designs each of its vaccine candidates to optimize the protective immune response to one or both of these antigens utilizing the distinctive plug-and-play nature of its proprietary MAPS™ technology platform, presenting the potential opportunity to make a significant step forward in addressing major healthcare challenges posed by novel and resistant infectious diseases. Affinivax was founded in 2014 with a seed investment from the Bill & Melinda Gates Foundation and an exclusive license to the MAPS technology from Boston Children’s Hospital. For more information, visit www.affinivax.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220104005322/en/
Contacts
Investor Contact
Stephen Jasper
Gilmartin Group, LLC
858-525-2047
Stephen@gilmartinir.com
Media Contact
Kathryn Morris
The Yates Network
914-204-6412
kathryn@theyatesnetwork.com
Source: Affinivax, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20220104005322/en
